Five pharmaceutical companies’ stock price strengthened, showing ‘elasticity’

(Health Korea News / Lee Si-woo) The stock prices of the five leading pharmaceutical companies engaged in domestic pharmaceutical manufacturing have been on the rise since the beginning of the year.

As of the 9th of the new year, foreigners made net purchases for 5 consecutive trading days, leading to the KOSPI rally. Although individual investors have been net selling for five trading days excluding the first day of the new year, stock prices are showing a solid trend as institutions also participate in buying. Some are hopeful that as stock prices, which were shaken by negative political events such as the sudden declaration of martial law last year, have been rebounding since the beginning of the year, this will have a positive effect on the direction of individual stocks in the future.

In fact, the stock prices of Yuhan Corporation (000100), Chong Kun Dang (185750), Daewoong Pharmaceutical (069620), Green Cross (006280), and Hanmi Pharmaceutical (128940), which are representative pharmaceutical stocks, are on average flat or maintaining an upward trend compared to the last trading day of last year.

As of the closing price on the 9th, Yuhan Corporation is recording 133,000 won per share, up 11.2% (13,500 won) from the closing price on December 30, 2024 (119,500 won). Although foreigners were net sellers of Yuhan Corporation for six consecutive trading days, the stock price maintained an upward trend. The clinical results of the combination therapy of the new lung cancer drug ‘Lecraza’ and Johnson & Johnson’s (J&J) ‘Librivant’ acted as positive news. Eugene Investment & Securities proposed a buy rating and a target price of 220,000 won.

Chong Kun Dang has been recording an upward trend for the past 7 consecutive trading days. The stock price also rose 6.5%P (5,800 won) from 89,000 won on December 30 last year to 94,800 won on the 9th. Daewoong Pharmaceutical is also up 4.98% (6,300 won) to 132,700 won, and Hanmi Pharmaceutical is up 1.24% to 284,000 won. Green Cross is the only one among the top five, recording 168,200 won, down 6.29% from the end of last year.

(Recent stock price (based on closing price) trends of the five pharmaceutical companies)

In the new year’s stock market, the flow of pharmaceutical-related stocks is showing a solid trend that meets market expectations. Major companies are also putting forth aggressive and active future visions and management strategies, such as developing innovative new drugs, improving efficiency through digital transformation, strengthening research and development, and expanding global expansion.

Experts said, “It is true that the pharmaceutical industry is facing difficulties such as fierce competition and changes in the regulatory environment, but each company must find a way out by securing a strategy and profit structure that suits them.” They added, “In particular, the impeachment situation, exchange rate instability, domestic demand recession, “I hope this will be a year in which we wisely overcome internal and external difficulties, such as the risk of Trump in the U.S., and strengthen the status of K-Pharmaceuticals,” he said.

Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited